A phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin

Marcellin, P.;Horsmans, Yves;Nevens, Frederik;Grange, JD;Alam, J;et.al.
(2004) 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver — Location: Berlin (Germany) (14.April.2004)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 62.92 KB
Request a copy

Details

Authors
  • Marcellin, P.
    Author
  • Horsmans, YvesUCLouvain
    Author
  • Nevens, FrederikUCLouvain
    Author
  • Grange, JD
    Author
  • Alam, J
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Marcellin, P., Horsmans, Y., Nevens, F., Grange, J., Bronowicki, J., Vetter, D., Kauffman, R., Knox, S., McNair, L., Moseley, S., & Alam, J. (2004). A phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin. Journal of Hepatology, 40, 145. https://doi.org/10.1016/S0168-8278(04)90492-8 (Original work published 2004)